Tag
Faecalibacterium prausnitzii EXL01, a single commensal bacterial strain, shows promise in preventing multiple-recurrent CDI by restoring key microbiome functions, including bile acid metabolism and butyrate production, with safety and effic
A 2025 Cochrane update finds probiotics may halve the relative risk of C. difficile-associated diarrhea in antibiotic-treated patients (ARR 1.6%, NNT 65) but evidence is low certainty and applicability varies with baseline risk.
Recent research confirms that antibiotic exposure doubles the risk of hospital-onset Clostridioides difficile infection (CDI), especially in non-carriers, underscoring the central role of antibiotic stewardship and the need for additional p
FMT is noninferior to vancomycin for primary CDI, with similar cure rates and safety, suggesting it may be a viable first-line therapy.
